Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma

Complete title: A Phase 1b, Multicenter, Open-Label Study of ACP-196 in Combination with Bendamustine and Rituximab (BR) in Subjects with Mantle Cell Lymphoma

Research Study Number 20160991
Principal Investigator Stephen Smith
Phase I

Research Study Description

To characterize the safety profile of ACP-196 in combination with bendamustine and rituximab in subjects with treatment naive and relapse/refractory Mantle Cell Lymphoma (MCL)

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20160991
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Hematologic Malignancies; Lymphoma; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin (NHL); Immunoproliferative Disorders; Lymphoma, Mantle-Cell; Immune System Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials